SCHEMBL18200734

SCHEMBL18200734

c1cc(-c2ccc(-c3nc(-c4ccc5ccccc5c4)nc(-c4ccc5ccccc5c4)n3)cc2)cc(-c2nc3ccccc3c3c2ccc2ccccc23)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
ATM Q13315 1/20 0.43
SMN1; SMN2 Q16637 3/20 0.38
CYP1A2 P05177 3/20 0.38
ALDH1A1 P00352 2/20 0.38
HSD17B10 Q99714 2/20 0.38
KDM4E B2RXH2 1/20 0.38
TP53 P04637 1/20 0.38
AURKA O14965 1/20 0.38
AURKB Q96GD4 1/20 0.38
NPC1 O15118 2/20 0.37
LMNA P02545 2/20 0.37
MAPT P10636 2/20 0.37
RAB9A P51151 2/20 0.37
HPGD P15428 1/20 0.37
NPY1R P25929 1/20 0.37
HTT P42858 1/20 0.37
NPY2R P49146 1/20 0.37
CYP3A4 P08684 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18200580 0.97 MEN1 (0.42) MEN1KMT2AATMSMN1; SMN2CYP1A2
SCHEMBL18200520 0.96 MEN1 (0.44) MEN1KMT2AATMSMN1; SMN2CYP1A2
SCHEMBL17034883 0.96 MEN1 (0.43) MEN1KMT2AATMSMN1; SMN2CYP1A2
SCHEMBL18200509 0.95 MEN1 (0.47) MEN1KMT2AATMSMN1; SMN2ALDH1A1
SCHEMBL18200934 0.94 MEN1 (0.48) MEN1KMT2AATMSMN1; SMN2CYP1A2
SCHEMBL18200825 0.94 MEN1 (0.49) MEN1KMT2AATMSMN1; SMN2CYP1A2
SCHEMBL18200882 0.94 MEN1 (0.44) MEN1KMT2AATMSMN1; SMN2CYP1A2
SCHEMBL18201212 0.93 CYP1A1 (0.43) MEN1KMT2AATMSMN1; SMN2CYP1A2
SCHEMBL18201122 0.93 MEN1 (0.47) MEN1KMT2AATMSMN1; SMN2CYP1A2
SCHEMBL18201045 0.93 MEN1 (0.46) MEN1KMT2AATMSMN1; SMN2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9728731-B2 Heterocyclic compound and organic light emitting device using same HEESUNG MATERIAL LTD. (KR) 2017-08-08 US disclosed
US-9728731-B2 Heterocyclic compound and organic light emitting device using same HEESUNG MATERIAL LTD. (KR) 2017-08-08 US disclosed
US-20160380208-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE USING SAME HEESUNG MATERIAL LTD. (KR) 2016-12-29 US disclosed
EP-3088392-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE USING SAME Heesung Material Ltd. (KR) 2016-11-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160380208-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE USING SAME NOTUM, DDT, CRY1 MEN1 1750/4885KMT2A 1104/4885ATM 2923/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.